 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...151152153154155156157158159160161...208209» |
- [VIRTUAL] Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_379;
Conclusions The safety and tolerability profile among the four approved PARP inhibitors are comparable in terms of SAE and AE-related discontinuation of treatment. Statistically significant differences in the AE spectrum and AE-related dose interruption and dose reduction demonstrated the prompt identification of adverse events and dose personalization seems mandatory to obtain maximal benefit from PARP inhibitors.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A prospective, randomized, controlled, multicenter phase III clinical trial of apatinib combined with neoadjuvant chemoradiotherapy for patients with locally advanced, HER2-negative, Siewert’s type II-III adenocarcinoma of esophagogastric junction () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_338;
P3
Enrollment is currently ongoing. Clinical trial information: NCT03986385.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Safety and efficacy of apatinib for non-surgical advanced esophageal cancer: A real-world study () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_295;
Cox multivariate regression analysis indicated ECOG score was independent prognostic factors for progression-free survival (95% confidence interval, 1.25 6.97 months, P=0.014). Conclusions For patients with advanced esophageal cancer, apatinib can prolong progression-free survival and overall survival, with tolerable adverse reactions.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A single-arm study of apatinib plus neoadjuvant chemotherapy followed by resection in patients with locally advanced colorectal adenocarcinoma () - Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_251;
7 patients (C-D classification 1-2, 14%) observed surgery-related complications. Conclusions Neoadjuvant chemotherapy combined with apatinib had shown considerable efficacy and controlled safety in patients with locally advanced colorectal cancer.
- |||| AiRuiKa (camrelizumab) / Incyte
Clinical: #ASCO21 ➡️R-H Xu, et al (abstr 4000) ✅Ph 3 trial of camrelizumab plus chemo vs. chemo in patients with advanced esophageal SCC 👉Paclitaxel + cis +/- camrelizumab 👉596 patients randomized 🎉Camrelizumab plus chemotherapy⬆️mOS (15.3 vs. 12.0 mos) and ⬆️ORR (72.1% vs. 62.1%) (Twitter) - Jun 1, 2021
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Apatinib treatment is effective for metastatic malignant phyllodes tumors of the breast: a case report. (Pubmed Central) - Jun 1, 2021
Conclusions Neoadjuvant chemotherapy combined with apatinib had shown considerable efficacy and controlled safety in patients with locally advanced colorectal cancer. The present case showed the potential therapeutic effects of apatinib in patients with MPT.
- || plinabulin (BPI 2358) / BeyondSpring
PDUFA date: $BYSI plinabulin PDUFA Nov 30th (Twitter) - Jun 1, 2021
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial, Intubation: Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults (clinicaltrials.gov) - Jun 1, 2021
P4, N=600, Not yet recruiting, Sponsor: Tongji Hospital
- Irene (pyrotinib) / Jiangsu Hengrui Medicine
[VIRTUAL] Meet Up - Meet the ASM Journal Editors: Exploring Open Access Journals at ASM (Projection Session Room) - May 31, 2021 - Abstract #WMF2021WMF_5610;
Irene Newton (MRA), Dr...Jack Gilbert (mSystems), and Dr. Stanley Maloy (JMBE).
- ||||| nemvaleukin alfa (ALKS 4230) / Alkermes, Keytruda (pembrolizumab) / Merck (MSD), SHR-1701 / Jiangsu Hengrui Medicine
Clinical, P1 data: #ASCO21 #PancreaticCancer And finally - a couple IO Phase 1 trials to👓 D Liu et al (abstr 2503) ➡️SHR-1701, a bifunctional PD-L1 & TGF-β inh ✅PR in a panc acinar Ca V Boni (abstr 2513) ➡️Nemvaleukin alfa (synth cytokine, binds to the IL-2R) + pembro ✅PR in 1 of 2 PDAC pts (Twitter) - May 31, 2021
- | Irene (pyrotinib) / Jiangsu Hengrui Medicine
Journal: Pyrotinib Sensitizes 5-Fluorouracil-resistant HER2+ Breast 4 Cancer Cells to 5-Fluorouracil. (Pubmed Central) - May 28, 2021
Moreover, in vivoexperiments demonstrated that pyrotinib in combination with 5-FU more effectivelyinhibited SKBR-3/FU tumor growth than either pyrotinib or 5-FU alone. In conclusion,our findings suggest that pyrotinib could restore sensitivity of 5-FU-resistant HER2+breast cancer cells to 5-FU through downregulating the expression levels of TS andABCG2.
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P3 trial: Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov) - May 27, 2021
P3, N=440, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2/3 trial: Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - May 27, 2021
P2/3, N=420, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health
Journal: Semi-fluorinated Alkane Eye Drops Reduce Signs and Symptoms of Evaporative Dry Eye Disease After Cataract Surgery. (Pubmed Central) - May 27, 2021
[J Refract Surg. 2020;36(7):474-480.].
- || AiTan (rivoceranib) / HLB Bio Group, Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Clinical, P2 data, Journal, Combination therapy, Circulating tumor DNA: Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. (Pubmed Central) - May 27, 2021
All-oral therapy with apatinib plus vinorelbine displayed objective efficacy in patients with heavily pretreated HER2-negative mBC, with acceptable and manageable toxicity profiles. Patients with no gene variant detected and lower variant allele frequencies in ctDNA at baseline showed longer PFS.
- ||| Stivarga (regorafenib) / Bayer
Enrollment open: Carelizumab Combined With Regorafenib in the Treatment of HCC?CARE-2020? (clinicaltrials.gov) - May 26, 2021
P2, N=69, Recruiting, Sponsor: Nanfang Hospital of Southern Medical University
Patients with no gene variant detected and lower variant allele frequencies in ctDNA at baseline showed longer PFS. Not yet recruiting --> Recruiting
- ||| GSK5784283 / GSK
New P1 trial: A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma (clinicaltrials.gov) - May 26, 2021
P1, N=62, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma (clinicaltrials.gov) - May 26, 2021
P2, N=40, Recruiting, Sponsor: Di Wu
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New P1 trial: SHR-3680: Relative Bioavailability Study of SHR3680 (clinicaltrials.gov) - May 26, 2021
P1, N=48, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - May 25, 2021
P2, N=30, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || SHR2285 / Jiangsu Hengrui Pharma
Trial completion, Enrollment change: The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects (clinicaltrials.gov) - May 25, 2021
P1, N=36, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | N=24 --> 36
- ||| SHR2285 / Jiangsu Hengrui Pharma
Enrollment open, Enrollment change, Trial completion date: The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects (clinicaltrials.gov) - May 25, 2021
P1, N=104, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Completed | N=24 --> 36 Not yet recruiting --> Recruiting | N=80 --> 104 | Trial completion date: Sep 2021 --> May 2021
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment open: Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer (clinicaltrials.gov) - May 25, 2021
P2, N=39, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting --> Recruiting | N=80 --> 104 | Trial completion date: Sep 2021 --> May 2021 Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: Pyramid: Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 25, 2021
P2, N=490, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: CAMERA: Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (clinicaltrials.gov) - May 25, 2021
P2, N=38, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group, Tagrisso (osimertinib) / AstraZeneca
Retrospective data, Journal: Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. (Pubmed Central) - May 25, 2021
The most common adverse events were hypertension (30.7%, 12/39), diarrhea (15.4%, 6/39), and proteinuria (12.8%, 5/39). The combination of apatinib and osimertinib improved the ORR and the DCR of patients with osimertinib-refractory EGFR-positive NSCLC, thus making it a reasonable treatment choice after the development of osimertinib resistance.
- || SHR2285 / Jiangsu Hengrui Pharma
Trial completion, Enrollment change: The PK/PD Study of SHR2285 Tablets in Healthy Subjects (clinicaltrials.gov) - May 24, 2021
P1, N=28, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
The combination of apatinib and osimertinib improved the ORR and the DCR of patients with osimertinib-refractory EGFR-positive NSCLC, thus making it a reasonable treatment choice after the development of osimertinib resistance. Not yet recruiting --> Completed | N=52 --> 28
- ||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Enrollment closed: A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (clinicaltrials.gov) - May 24, 2021
P3, N=1192, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Completed | N=52 --> 28 Recruiting --> Active, not recruiting
- |||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment open: DAWNA-A: Phase III Study ?SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative (clinicaltrials.gov) - May 24, 2021
P3, N=4350, Enrolling by invitation, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial, Real-world evidence, Real-world, Metastases: Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - May 24, 2021
P, N=100, Active, not recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- Ukoniq (umbralisib) / TG Therap, Utuxin (ublituximab) / TG Therap, TG-1701 / TG Therap
[VIRTUAL] TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies () - May 22, 2021 - Abstract #ICML2021ICML_447;
P1
The combination of 1701+U2 has been well tolerated and dose escalation continues. The combination shows enhanced depth of response over TG-1701 monotherapy.
- TG-1701 / TG Therap
[VIRTUAL] Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in B-cell non-Hodgkin lymphoma () - May 22, 2021 - Abstract #ICML2021ICML_433;
Altogether, these data validate phosphoproteomic as a valuable tool for the early detection of response to BTK inhibition in the clinic, and for the determination of drug mechanism of action. Our results also support the use of TG-1701-U2 combination in R/R B-NHL patients, irrespective of prior response to ibrutinib.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab Combined with GEMOX in Patients with Relapsed or Refractory Hodgkin Lymphoma () - May 22, 2021 - Abstract #ICML2021ICML_399;
P2
Our results also support the use of TG-1701-U2 combination in R/R B-NHL patients, irrespective of prior response to ibrutinib. The preliminary data obtained so far suggests that camrelizumab combined with GEMOX chemotherapy has encouraging clinical efficacy and tolerable toxicity in R/R HL patients and merits continuous study.
- linperlisib (YY-20394) / Shanghai YingLi Pharma
[VIRTUAL] A Phase Ib study of an oral PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T cell lymphoma () - May 22, 2021 - Abstract #ICML2021ICML_309;
P1
Linperlisib showed significant activity in r/r PTCL patients and was well tolerated with manageable toxicities. With these promising findings, further study of the treatment of PTCL by Linperlisib is warranted.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial. (Pubmed Central) - May 22, 2021
With these promising findings, further study of the treatment of PTCL by Linperlisib is warranted. Apatinib combined with single-agent chemotherapy may be a novel option for second-line treatment of advanced NSCLC.
- || Irene (pyrotinib) / Jiangsu Hengrui Medicine
Review, Journal: HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. (Pubmed Central) - May 22, 2021
There is increasing interest in utilizing these drugs in combination with chemotherapy and /or other HER2-directed agents in patients with central nervous system involvement, TKIs have shown to be effective in this setting for which treatment options have been previously limited and the prognosis remains poor. The aim of this review is to summarize currently approved TKIs for HER2+ breast, key clinical trials, and their use in current clinical practice.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study. (Pubmed Central) - May 21, 2021
The aim of this review is to summarize currently approved TKIs for HER2+ breast, key clinical trials, and their use in current clinical practice. Apatinib should be an effective and tolerable treatment option for patients with metastatic, recurrent cervical cancer after failure of radiotherapy and first-line chemotherapy.
- || hetrombopag (SHR 8735) / Jiangsu Hengrui Medicine
Clinical, PK/PD data, Journal: Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers. (Pubmed Central) - May 21, 2021
P1
Thus, hetrombopag should be taken in a fasted state to avoid the impact of food on bioavailability and platelet counts. ClinicalTrials.gov identifier: NCT02409394.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma. (Pubmed Central) - May 21, 2021
Cox multivariate regression analysis indicated T stage and short-term efficacy were independent prognostic factors for overall and progression-free survival. CONCLUSIONS For patients with locally advanced esophageal squamous cell carcinoma, combining Apatinib with concurrent chemoradiotherapy can improve patient survival and significantly prolong progression-free survival, with tolerable adverse reactions.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Irene (pyrotinib) / Jiangsu Hengrui Medicine
Clinical, Retrospective data, Review: Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis. (Pubmed Central) - May 21, 2021
These results indicate that Pyr may be more effective than T-DM1 in HER2+ MBC patients pre-treated with Tra and a taxane. However, it may be associated with more grade ≥3 AEs.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, P2 data, Journal: Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study. (Pubmed Central) - May 21, 2021
P2
The AEs were mild, mainly in grade 1 or 2, and no toxicity-induced death occurred. Apatinib monotherapy is an effective and promising regimen for treating patients with advanced cholangiocarcinoma who experienced failure of gemcitabine-based chemotherapy.
- || dalpiciclib (SHR6390) / Jiangsu Hengrui Medicine
#1002 中国の新規CDK4/6iのDalpiciclibのphase3試験。 アブストラクトからは効果や副作用など、PALOMA3とすごく似ている印象を受けました。 が、遅ればせながらも自国のCDK4/6iでphase3まで持ってくるとは、国力を感じます… https://t.co/EK7KOFFTgS #ASCO21 (Twitter) - May 20, 2021
- [VIRTUAL] From Biology to Therapy: Progress in Hodgkin Lymphoma () - May 20, 2021 - Abstract #SOHO2021SOHO_249;
The field of immunotherapy in classic HL is now moving toward the use of newer PD-1 inhibitors such as sintilimab, tislelizumab and camrelizumab,21–23 bispecific antibodies such as AFM-13,24 cellular therapies using CD30 chimeric antigen T-cells (CD30.CART)25 and anti-CD25 antibody-drug conjugates such as camidanlumab tesirine (cami-T).26 These therapies engage other cells within the microenvironment, deplete regulatory T-cells, or activate T-cells despite loss of MHC molecules...Future studies are required to understand which drugs to use together but also the sequence in which they should be administered. A rational approach to combining targeted agents with standard therapies will likely result in an improved outcome for patients.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Retrospective data, Journal: Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study (Pubmed Central) - May 20, 2021
All adverse reactions were effectively controlled. Camrelizumab combined with apatinib can effectively prolong the survival period of patients with mid-and advanced-stage HCC, and it is well tolerated.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, P2 data, Journal: Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study. (Pubmed Central) - May 20, 2021
P2
An encouraging PFS, a high ORR, and a manageable safety profile were observed in this study. It seems that the administration of apatinib in R/MACCHN is likely to have a clinically meaningful therapeutic benefit and warrants further investigation.This study was prospectively registered in ClinicalTrials.gov (NCT02775370; date of registration: 17 May 2016; date of first patient enrollment: 25 May 2016).
- | Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
Retrospective data, Journal: Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. (Pubmed Central) - May 20, 2021
P
Pyrotinib plus capecitabine has been approved in China for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC)...Nearly all patients (97.9%) had received trastuzumab and 50.5% were administered lapatinib...Oral vinorelbine is a useful alternative to the intravenous form when combined with pyrotinib. [ClinicalTrials.gov], identifier [NCT04517305].
- || TG-1701 / TG Therap
Great combo data @chanyooncheah @TGTherapeutics @SagarLonialMD to be presented at #ASCO21. When will the U2 + TG-1701 + VX going to start? Any other new TG-1701 combos in the future? $TGTX (Twitter) - May 19, 2021
- | AiTan (rivoceranib) / HLB Bio Group
Trial primary completion date, IO biomarker: Neoadjuvant Immunotherapy for Resectable Gastric Cancer (clinicaltrials.gov) - May 19, 2021
P2, N=30, Recruiting, Sponsor: Qilu Hospital of Shandong University
[ClinicalTrials.gov], identifier [NCT04517305]. Trial primary completion date: Dec 2020 --> Dec 2021
- | AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Enrollment closed: Icemelting: Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma (clinicaltrials.gov) - May 17, 2021
P1, N=21, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Dec 2020 --> Dec 2021 Recruiting --> Active, not recruiting
- || AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: CAPSTONE: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (clinicaltrials.gov) - May 17, 2021
P2, N=28, Not yet recruiting, Sponsor: Qian Chu